Download ProgramWMMC2012-12-12-2011 - congresos

6th World Meeting of Interdisciplinary
Melanoma/Skin Cancer Centers
& 8th EADO Congress
14th - 17th November 2012
Draft of the Scientific Program
Introduction
Since the first World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers, which took
place in Barcelona, Spain, in September 2007, this congress became a success story. It is
an opportunity where clinicians and researchers, who are part of multidisciplinary melanoma
centers can interact, learn from one another, establish collaborations and set an agenda for
the further evolution of multidisciplinary melanoma care and research. In November 2012,
this meeting will be combined with the likewise well-established EADO congress, and the
focus will be on melanoma, cutaneous lymphoma and epithelial skin cancers.
This conference is specifically designed to attract young investigators and skin cancer treating physicians in the field. All contributions submitted have to be presented as
posters, and 9 poster prices will be given for clinical topics, translational research and basic
research. We avoid “free communications”, however 18 contributions will be additionally
selected for presentation in the plenary sessions.
The Plenary Sessions will form the scientific backdrop for the meeting, and will highlight
problem areas and opportunities in melanoma today. These Plenary Sessions will set the
stage for a series of Breakout Sessions, designed to focus attention and lead to new collaborative approaches in key areas where melanoma/skin cancer centers should be taking
the lead.
The Breakout Sessions will address the following topics:

Messages for Skin Cancer Prevention
Goals: To develop the right messages for future prevention campaigns. Despite many
prevention campaigns since decades the incidence of melanoma and other skin cancers
still rises. The question must be asked, if we delivered the right messages in the past.

Guideline-Development and International Cooperation
Goals: To develop strategies for an international cooperation in guideline development.
This session shall primarily focus on melanoma. In several countries, guidelines for melanoma have been developed based on a systematic literature research and on a formal
consensus process. The question shall be addressed, whether an international
knowledge basis can be established, and how this can be continuously updated.

Building up internationally accepted documentation schedules and standards
It is a standard for skin cancer/melanoma centers to document the patients in a way that
allows evaluations for many questions of prognosis and management. It would be advantageous, to standardize the documentation schedules internationally.

Quality Criteria for Skin Cancer Centers
Goals: To establish quality criteria for the work of skin cancer centers/programs which are
internationally accepted. Skin cancer centers with interdisciplinary tumor boards have
been developed in many countries, and in some countries already formal certification
processes have been applied.

Pathway development for Skin Cancer Centers
Goals: To exchange the experience of pathway development for melanoma and other
skin cancers in different disease stages. Methods of the development, methods of implementation into clinical practice and major contents of these pathways shall be communicated..

Strategies for Melanoma Follow-up Examinations
Goals: To develop recommendations for the follow-up of melanoma patients which could
guide the practice in different countries and to consider clinical trials which could broaden
the body of evidence for the melanoma follow-up or for giving up these examinations.
The results of the outbreak sessions will be presented by the chairpersons in the following
sessions. Thus, all persons attending the conference will be informed on the very recent recommendations for burning questions in melanoma and skin cancer management.
The conference will as a main emphasis address new treatment developments for melanoma
and other skin cancers. Already the first session will deal with new treatment options and
new clinical trials. It is a major goal of this congress, to cover all new developments and to
provide the possibility to discuss the new treatment approaches. A deep insight into the future advances in skin cancer therapy will also be provided by sponsored symposia by the
pharmaceutical companies.
Furthermore, the different aspects of epidemiology and prevention, early detection and new
diagnostic tools and of histopathologic diagnosis will be covered. Melanoma surgery and
immunotherapy will be discussed in own sessions. Cutaneous lymphoma, actinic keratosis
and advanced epithelial cancers are additional topics with own sessions. Thus, an update of
all aspects of skin cancer is provided. We look forward to seeing you in Barcelona in November 2012!
Claus Garbe, Tuebingen, Germany
Axel Hauschild, Kiel, Germany
Josep Malvehy, Barcelona, Spain
Vernon Sondak, Tampa, FL., USA
John Thompson, Sydney, Australia
Program
Wednesday, November 14th, 2012
14.00 –
17.30
Plenary Session 1:
New drugs and new studies (no ASCO
slides allowed)
Chairpersons:
Claus Garbe,
Axel Hauschild
MAGE-3 ASCI
Brigitte Dreno
Nantes, France
Conventional and Pegylated interferon
Peter Mohr,
Buxtehude, Germany
PD-1 Antibodies
Paolo Ascierto
Naples, Italy
Ipilimumab
Caroline Robert
Paris, France
Darleukin
Thomas Eigentler,
Tübingen,
Germany
OncoVex GM-CSF
Robert Coffin
Woburn, USA
Adoptive T-cell transfer
Benjamin Weide,
Tübingen, Germany
Vemurafenib: new trials
Claus Garbe, Tübingen, Germany
GSK2118436 BRAF inhibitor
Axel Hauschild,
Kiel, Germany
AZD6244 MEK inhibitor
Reinhard Dummer
Zurich, Switzerland
GSK1120212 MEK inhibitor
Georgina Long
Sydney, Australia
C-KIT inhibitors
Carola Berking,
Munich, Germany
Multi VEGF inhibitor (E7080)
Ralf Gutzmer,
Hannover, Germany
nab-paclitaxel (Abraxane®)
Sanjiv S. Agarwala. Bethlehem,USA
Electrochemotherapy
Alessandro Testori
Milan, Italy
18.00 –
19.00
20.00
Sponsored Symposium 1 (Plenary) Roche
Proposed
What we have learned about BRAF mutations
Richard Kefford,
Sydney, Australia
BRAF inhibition: principal effects and adverse events
Keith Flaherty,
Boston, USA
Update on BRIM trials
Paul Chapman;
New York, USA
Welcome Reception
Thursday, November 15th, 2012
8.00 –
9.00
Guided Poster Tour 1 (3 Poster Prices of
500 € each)
9.00 –
10.30
Plenary Session 2:
Epidemiology and prevention of melanoma
Chairpersons:
Jean-Jacques Grob,
Veronique del Marmol
Incidence and mortality development: Have we
reached a plateau or decrease?
Ulrike Leiter, Tübingen,
Germany
Beliefs of European populations: Do we deliver the
right messages?
Veronique del Marmol,
Brussels, Belgium
Early detection by lays: How to improve the performance?
Jean-Jacques Grob,
Marseilles
Selected submitted abstract
NN
Selected submitted abstract
NN
Selected submitted abstract
NN
10.30 –
11.00
Break
11.00 –
12.30
Plenary Session 3:
New diagnostics of melanoma
Chairpersons:
Hubert Pehamberger,
Josep Malvehy
What is new in dermoscopy?
Josep Malvehy, Barcelona, Spain
The strength of in-vivo confocal laser microscopy
Giovanni Pellacani,
Modena, Italy
Tumor markers in melanoma
Maja Hofmann, Berlin,
Germany
Selected submitted abstract
NN
Selected submitted abstract
NN
Selected submitted abstract
NN
12.30 –
13.00
Key Note Lecture 1:
The hall marks of melanomagenesis and
its targeting
Maria Soengas
13.00 –
14.00
Sponsored Lunch Symposium 2 (Plenary) Avene
What we have learned about improving early detection
of melanoma
Allan Halpern, New
York, USA
The German skin cancer screening examinations program and outcomes
Peter Mohr, Buxtehude, Germany
The EADO/Avene Campaign for early melanoma detection
JJ Grob, Marseille,
France
Thursday, November 15th, 2012
14.00 –
15.30
Breakout Sessions
Chairpersons
Messages for Skin Cancer Prevention
Carola Berking, Allan
Halpern, Ketty Peris
Guideline-Development
tional Cooperation
Stephan Grabbe,
Philipp Saiag, John
Thompson
and
Interna-
14.00 –
15.30
Free Communications
15.30 –
16.00
Break
16.00 –
17.30
Plenary Session 4:
Histopathological and Molecular Diagnosis of Melanoma
17.30 18.30
Sponsored Symposium 3 (Plenary)
MSD: Kirkwood, Sondak, Eggermont
Judith Olah, Jose Majordomo
Jürgen Bauer, Jane
Messina
18.30 18.50
Report from breakout sessions
18.50
End of Sessions
Friday, November 16th, 2012
8.00 –
9.00
Guided Poster Tour 2 (3 Poster Prices
of 500 € each)
9.00 –
10.30
Plenary Session 5:
Melanoma Surgery
10.30 –
11.00
Break
11.00 –
12.30
Plenary Session 6:
Melanoma Immunotherapy
Carolin Robert,
Dirk Schadendorf
12.30 –
13.00
Key Note Lecture 2:
Rational Strategies for Combining
Targeted Drugs
Keith Flaherty
13.00 –
14.00
Sponsored Lunch Symposium 4 (Plenary)BMS: Ribas, Robert, Wolchok
14.00 –
15.30
Breakout Sessions
Chairpersons:
Alexander Eggermont,
Vernon Sondak
Quality Criteria for Skin Cancer Centers
Claus Garbe, Vernon
Sondak, John Thompson
Strategies for Melanoma Follow-up
Examinations
Veronique del Marmol,
Ulrike Leiter, Susana Puig
14.00 –
15.30
Free Communications
Sibel Alper, Salvador Mar-
15.30 –
16.00
Break
16.00 –
17.30
Plenary Session 7:
Cutaneous Lymphoma
16.00 –
17,30
Course:
Good Clinical Practice 1
17.30 18.30
Sponsored Symposium 5 (Plenary)
Almirall?:
18.30 18.50
Report from breakout sessions
tin Algarra
Martin Bagot, Reinhard
Dummer, Rudolf Stadler
18.50
End of Sessions
Saturday, November 17th, 2012
8.00 –
9.00
Guided Poster Tour 3 (3 Poster Prices
of 500 € each )
9.00 –
10.30
Plenary Session 8:
Actinic Keratoses
10.30 –
11.00
Break
11.00 –
12.30
Plenary Session 9:
Advanced Epithelial Cancer
Alexander Stratigos,
Jürgen Becker
12.30 –
13.00
Key Note Lecture 3:
The Future of Comprehensive Cancer
Centers
Alexander Eggermont
13.00 –
14.00
Sponsored Lunch Symposium 6 (Plenary) Leo PEP005 (Stockfleth, Becker)
14.00 –
18.00
Courses
Dermoscopy
Medical Tumor Treatment
Good Clinical Practice 2
Chairpersons:
Colin Fleming, Eggert
Stockfleth
Proposed Faculty
1.
Sanjiv S. Agarwala, MD
Professor of Medicine
Temple University School of Medicine
Chief, Oncology & Hematology
St. Luke’s Cancer Center
Bethlehem, PA, USA
Phone: +1 610 2970169
E-Mail: [email protected]
2.
Salvador Martin Algarra, Pamplona, Spain
3.
Sibel Alper, Izmir, Turkey
4.
Peter ArenbergerPrague, Czech Republic
5.
Giuseppe Argenziano, Reggio Emilia, Italy
6.
Martine Bagot, Paris, France
7.
Jürgen Bauer, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Straße 25
72076 Tuebingen, Germany
Phone: +49 7071 2984585
E-Mail: [email protected]
8.
Jürgen Becker, MD
Professor of Dermatology
Department of Dermatology
Medical University of Graz
Auenbruggerplatz 8
8036 Graz, Austria
Phone: 0316 385 12538
E-Mail: [email protected]
9.
Rafael Botella, Valencia, Spain
10.
Francisco Camacho, Sevilla, Spain
11.
Carola Berking, MD
Professor of Dermatology
Department of Dermatology
Ludwig Maximilians University
Frauenlobstraße 9–11
80337 Munich, Germany
Phone: +49 89 51476010
E-Mail: [email protected]
12.
Veronique del Marmol, Bruxelles, Belgium
13.
Brigitte Dreno, MD
Professor of Dermatology
Department of Dermatology
University of Nantes
CHU Nantes
Place Alexis Ricordeau
44093 Cedex 01, France
Phone: +33 240 083118
E-Mail: [email protected]
14.
Reinhard Dummer, MD
Professor of Dermatology
Department of Dermatology
Universitätsspital Zurich
Gloriastrasse 31
CH-8091 Zurich, Switzerland
Phone: +41 44 2552507
E-Mail: [email protected]
15.
Alexander M. M. Eggermont, MD, PhD
Professor of Surgery
Directeur Général, Institut de
Cancérologie Gustave Roussy
114 Rue Edouard Vaillant
94800 Villejuif/Paris, France
Phone: +33 142 114016
E-Mail: [email protected]
16.
Thomas Eigentler, MD
Department of Dermatology
Eberhard Karls University
Liebermeister Straße 25
72076 Tuebingen, Germany
Phone: +49 7071 2985748
E-Mail: thomas.eigentler@med.
uni-tuebingen.de
17.
Alexander Enk, MD
Professor of Dermatology
Director, Department of Dermatology
University of Heidelberg
Voßstraße 2
69115 Heidelberg, Germany
Phone: +49 6221 56 8501
E-Mail: [email protected]
18.
Keith T. Flaherty, MD
Professor of Oncology
Director, Developmental Theraupeutics
Massachusetts General Hospital
Cancer Center
55 Fruit Street, Yawkey 9E
Boston, MA 02114, USA
Phone: 617 726-4800
E-Mail: [email protected]
19.
Colin Fleming,Dundee, UK
20.
Claus Garbe, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Straße 25
72076 Tuebingen, Germany
Phone: +49 7071 2987110
E-Mail: [email protected]
21.
Helen Gogas, MD
Professor of Oncology
Medical School, University of Athens
24 Karneadou STR
Athens 10675, Greece
Phone: +30 69 44 68 1159
E-Mail: [email protected]
22.
Stephan Grabbe, MD
Professor of Dermatology
Director
Department of Dermatology
University Mainz
Langenbeckstraße 1
55131 Mainz, Germany
Phone: +49 6131 177112
E-Mail: [email protected]
23.
Jean-Jacques Grob, MD
Professor of Dermatology
Service de Dermatologie
Hopital Ste Marguerite
270 Av Ste Marguerite
13274 Marseille Cedex 09, France
Phone: +33 491 744714
E-Mail: [email protected]
24.
Ralf Gutzmer, MD
Professor of Dermatology
Dept. of Dermatology
Hannover Medical School
Hauttumorzentrum
Recklingerstraße 5
30449 Hannover, Germany
Phone: +49 511 9246-0
E-Mail: [email protected]
25.
Allan Halpern, MD
Professor of Dermatology
Chief, Dermatology Service
Memorial Sloan Kettering Cancer Center
160 E 53rd St
New York NY 10022, USA
Phone: +1 212 6100133
E-Mail: [email protected]
26.
Axel Hauschild, MD
Professor of Dermatology
Department of Dermatology
University of Kiel
Schittenhelmstraße 7
24105 Kiel, Germany
Phone: +49 431 5971852
E-Mail: [email protected]
27.
Maja Hofmann, MD
Dept. of Dermatology
Charité
Charitéplatz 1
10117 Berlin, Germany
Phone: +49 30 450518069
E-Mail: [email protected]
28.
Roland Kaufmann, MD
Professor of Dermatology, Director
Department of Dermatology
Clinical Center J. W. Goethe University
Theodor-Stern-Kai 7
60590 Frankfurt/Main, Germany
Phone: +49 69 63015311
E-Mail: [email protected]
29.
Richard Kefford, MD, PhD
Professor of Medicine University
of Sydney, Westmead Hospital
Director Westmead Institute
for Cancer Research
Co-Director of Research Melanoma
Institute Australia
Department of Medicine
Westmead Hospital
Westmead, Sydney, NSW Australia
Phone: +61 2 9845 8089
E-Mail: [email protected]
30.
John M. Kirkwood, MD
Usher Professor of Medicine
and Dermatology
University of Pittsburgh School of Medicine
Director, Melanoma and
Skin Cancer Program
University of Pittsburgh Cancer Institute
Hillman Research Suite L1.32c
5115 Centre Avenue
Pittsburgh PA 15213-2584, USA
Phone: +1 412 6237707
E-Mail: [email protected]
31.
Harald Kittler, Vienna, Austria
32.
Céleste Lebbé, Paris, France
33.
Ulrike Leiter, MD
Department of Dermatology
Eberhard Karls University
Liebermeister Straße 25
72076 Tübingen, Germany
Phone: +49 7071 2984596
E-Mail: [email protected]
34.
María Isabel Longo, Madrid, Spain
35.
Paul Lorigan, MD, FRCP
Senior Lecturer and Consultant
in Medical Oncology
School of Cancer and Imaging Sciences
University of Manchester
c/o The Christie NHS Foundation Trust
Wilmslow Road, Withington
Manchester M20 4BX, UK
Phone: +44 161 446 8002
E-Mail: [email protected]
36.
Michele Maio, MD
Professor of Oncology
Department of Oncology
University Hospital of Siena
Strada delle Scotte n° 14
53100 Siena, Italy
Phone: +39 577 586336
E-Mail: [email protected]
37.
Josep Malvehy, MD
Coordinator of the Melanoma Unit
Hospital Clínico de Barcelona
C/Villarroel 170.08036 Barcelona, Spain
Phone: +34 93 22754002422
E-Mail: [email protected]
38.
Jerry Marsden, Birmingham, UK
39.
Daniela Massi, Florence, Italy
40.
José Mayordomo, MD
Professor of Oncology
Divison of Medical Oncology
University Hospital Zaragoza
50009 Zaragoza, Spain
Phone: +34 976760000
E-Mail: [email protected]
41.
Friedegund Meier, MD
Professor of Dermatology
Department of Dermatology
Eberhard Karls University
Liebermeister Straße 25
74076 Tuebingen, Germany
Phone: +49 7071 2984500
E-Mail: [email protected]
42.
Jane Messina, MD
Dermatopathologist
Moffi tt Cancer Center
12901 Bruce B Downs Boulevard
Tampa, FL 33612, United States
Phone: +1 813 9743133
E-Mail: Jane.Messina@moffi tt.org
43.
Peter Mohr, MD
Center of Dermatology
Elbeklinikum Buxtehude
Am Krankenhaus 1
21614 Buxtehude, Germany
Phone: +49 4161 7036209/-6250
E-Mail: [email protected]
44.
David Moreno, Sevilla, Spain
45.
Eduardo Nagore, Valencia, Spain
46.
Judith Oláh, MD
Department of Dermatology
and Allergology
University of Szeged
6720 Szeged, Hungary
E-Mail: [email protected]
47.
Poulam Patel, MD
Professor of Oncology
Nottingham University Hospitals
City Campus
Hucknell Road, Nottingham
NG51PB UK
Phone: +44 115 8231850
E-Mail: [email protected]
48.
Hubert Pehamberger, MD
Professor of Dermatology
Director, Department of Dermatology
University of Vienna
Währinger Gürtel 18–20
1090 Vienna, Austria
Phone: +43 1 404007710
E-Mail: hubert.pehamberger@
meduniwien.ac.at
49.
Giovanni Pellacani, Modena, Italy
50.
Ketty Peris, MD
Professor of Dermatology
Department of Dermatology
University of L’Aquila
Via Vetoio - Coppito 2
67100 L’Aquila, Italy
Phone: +39 0862433558
E-Mail: [email protected]
51.
Susana Puig, MD
Melanoma Unit
Dermatology Department
Hospital Clinic
Villarroel 170
08036 Barcelona, Spain
Phone: +34 93 2275400
E-Mail: [email protected]
52.
Antoni Ribas, MD
Professor of Oncology
Department of Oncology
11-934 Factor Bldg
UCLA Medical Center
10833 Le Conte Ave
Los Angeles CA 90095, USA
Phone: +1 310 2063928
E-Mail: [email protected]
53.
Caroline Robert, MD
Professor of Dermatology
Head of the Dermatology Unit
Institute Gustave Roussy
39 rue Camille Desmoulins
94805 Villejuif Cedex, France
Phone: +33 142 114210
E-Mail: [email protected]
54.
Philippe Saiag, MD
Professor of Dermatology
Head of Service de Dermatologie
Générale et Oncologique
Faculty of medicine Paris-Ile de
France Ouest
University of Versailles SQY
CHU A Paré 92104 Boulogne
Cedex, France
Phone: +33 49 095673
E-Mail: [email protected]
55.
Dirk Schadendorf, MD
Professor of Dermatology
Director, Department of Dermatology
University Hospital Essen
Hufelandstraße 55
45122 Essen, Germany
Phone: +49 201 7232430
E-Mail: [email protected]
56.
Vernon Sondak, MD
Professor of Surgery
Chief, Division of Cutaneous Oncology
Director of Surgical Education
H. Lee Moffitt Cancer Center and
Research Institute
12902 Magnolia Drive Tampa
FL 33612, USA
Phone: +1 813 7458788
E-Mail: [email protected]
57.
Rudolf Stadler, MD
Professor of Dermatology
Director, Department of Dermatology
Medical Center Minden
Hans-Nolte-Straße 1
32429 Minden, Germany
Phone:+49 571 7904501
E-Mail: [email protected]
58.
Eggert Stockfl eth, MD
Professor of Dermatology
University Hospital of Dermatology
Charitéplatz 1
10117 Berlin, Germany
Phone:+49 30 450518266
E-Mail: [email protected]
59.
Alexander Stratigos, MD
Professor of Dermatology
Department of Dermatology
University of Athens
28 Voucourestiou Street
Athens 10671, Greece
Phone: +30 210 361223
E-Mail: [email protected]
60.
Maria Soengas, Madrid, Spain
61.
Alessandro Testori, MD
Director
Melanoma and muscle-cutaneous
sarcomas Division
Istituto Europeo di Oncologia
Via Ripamonti 435
20141 Milan, Italy
Phone: +39 02 57489459493
E-Mail: [email protected]
62.
Luc Thomas, Lyon, France
63.
John Thompson, MD
Professor of Surgery
Director of the Sydney
Melanoma Unit
Level 2
1A Eden Street
North Sydney NSW 2060, Australia
Phone: +61 29911 7366
E-Mail: [email protected]
64.
Uwe Trefzer, MD
Professor of Dermatology
Department of Dermatology
Charité Berlin
Skin Cancer Center Charité
Charitéplatz 1
10117 Berlin, Germany
Phone: +49 30 450518016
E-Mail: [email protected]
65.
Benjamin Weide, MD
Dept. of Dermatology
Eberhard Karls University
Liebermeister Straße 25
72076 Tuebingen, Germany
Phone: +49 7071 2985748
E-Mail: [email protected]
66.
Iris Zalaudek, Graz, Austria